IN

Incanthera plc

Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.

INC | Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BGL7YW15 (+1 more)
LEI:
2138002HEV4UFBOEXQ97
Country:
United Kingdom
Address:
C/O GATELEY LEGAL, M2 4WU MANCHESTER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Incanthera plc is a therapeutics company specializing in the fields of dermatology and oncology. The company focuses on discovering and developing targeted solutions and transformative treatment technologies to address unmet medical needs. It leverages unique formulation and delivery technologies for its product pipeline. Incanthera's current commercial focus is its proprietary skincare brand, SKIN + CELL, which offers dermatological applications developed from its core technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 15:40
Post-Annual General Meeting Information
Result of AGM
English 32.4 KB
2025-11-06 08:30
Pre-Annual General Meeting Information
AGM 2025 Update
English 16.0 KB
2025-10-16 11:15
Investor Presentation
Proactive Investor Forum Presentation
English 18.0 KB
2025-10-14 08:00
Pre-Annual General Meeting Information
Notice of AGM
English 20.7 KB
2025-08-11 08:00
Earnings Release
SKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES
English 21.4 KB
2025-08-06 08:00
Regulatory News Service
SKIN + CELL TO LAUNCH
English 24.3 KB
2025-07-09 08:00
Major Shareholding Notification
Holding(s) in Company
English 52.6 KB
2025-06-30 08:00
Share Issue/Capital Change
Subscription, Directors' Dealing and RPT
English 51.7 KB
2025-06-18 08:00
Environmental & Social Information
New Findings on Protective Effects of Skin + CELL
English 21.1 KB
2025-03-28 08:00
Regulatory News Service
Commercial Update
English 19.0 KB
2025-03-25 16:08
Legal Proceedings Report
Resolution of Allegations of Patent Infringement
English 19.3 KB

Automate Your Workflow. Get a real-time feed of all Incanthera plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Incanthera plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Incanthera plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CORESTEMCHEMON Inc. Logo
Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.
South Korea 166480
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO
CorMedix Inc. Logo
Develops a catheter lock solution to prevent bloodstream infections in hemodialysis patients.
United States of America CRMD
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland COS
COSMO Pharmaceuticals N.V. Logo
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
Netherlands COPN
Cosmos Health Inc. Logo
A global healthcare firm developing & distributing nutraceuticals, generics, and OTC medications.
United States of America COSM
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Logo
Biotech firm developing cell therapies for regenerative medicine and immunotherapy applications.
United States of America CELZ
CRESCENT BIOPHARMA, INC. Logo
A biotech company developing bispecific antibody therapies to treat solid tumors.
United States of America CBIO
Crinetics Pharmaceuticals, Inc. Logo
Develops novel therapeutics for rare endocrine diseases and related tumors.
United States of America CRNX
CRISPR Therapeutics AG Logo
Develops transformative CRISPR gene-based medicines for diseases like sickle cell.
United States of America CRSP

Talk to a Data Expert

Have a question? We'll get back to you promptly.